Tamabian Mitsubishi submits Application for New Drug for Vadadustat to Japan's Ministry of Health, Labour and Welfare

Recently, Akebia Therapeutics announced that its partner, Mitsubishi Tanaka, has submitted Vadadustat'sNew Drug(http://Listing Application (JNDA) to Japan's Ministry of Health, Labour and Welfare for the treatment of chronic kidney disease (CKD) anemiaAbout Vadadustat
Vadadustat is an oxygen-deficient inducing factor protalude hydroxylase oral inhibitor (HIF-PHI) developed by AkebiaIn 2015, Mitsubishi Tanaka announced that it would join forces with Akebia to conduct Phase III clinical studies in Vadadustat and commercialization activities in the Asian marketIn return, Tamabian has the right to manufacture and sell the drug in Japan and will receive 20 per cent of its sales revenue in the Asian marketVadadustat's mechanism is to simulate the body's physiological response to hypoxia at high altitudes, where the body's response to oxygen scarcity is to improve hIF productionHIF regulates the mobilization of iron and the production of EPO to stimulate the production of red blood cells, thereby improving oxygen transportIf approved, Vadadustat will provide an oral treatment option for this class of patients and may become a new standard for the treatment of renal anemiaRecent clinical studies have shown that Vadadustat restores bloodmog levels in patients, and that thisdrug(http://also demonstrates good safetyThetrial(http://data submitted included positive top-line data from two phase 3 trials, one of which assessed the efficacy and safety of Vadadustat in patients with chronic kidney disease, and the other, a three-arm study conducted by twocompanies(http://announced in March 2019 in coitone and hemodialysis patients